Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature

Int J Antimicrob Agents. 2021 Jan;57(1):106174. doi: 10.1016/j.ijantimicag.2020.106174.

Authors

Jason D Goldman¹, George Diaz², Walter J Urba³

Affiliations

¹ Divisions of Infectious Disease and Organ Transplant, Swedish Medical Center, Seattle, WA, United States. Electronic address: jason.goldman@swedish.org.
² Divisions of Infectious Disease, Providence Regional Medical Center, Everett WA, United States.
³ Divisions of Hematology and Medical Oncology, Providence Cancer Institute Franz Clinic, Portland, OR, United States.

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / therapeutic use
Antimalarials / therapeutic use
Antiviral Agents / therapeutic use*
Azithromycin / therapeutic use*
COVID-19 / virology
COVID-19 Drug Treatment*
Clinical Trials as Topic
Drug Combinations
Drug Repositioning
Humans
Hydroxychloroquine / therapeutic use*
Politics
SARS-CoV-2 / pathogenicity*
Uncertainty

Substances

Anti-Bacterial Agents
Antimalarials
Antiviral Agents
Drug Combinations
Hydroxychloroquine
Azithromycin

Grants and funding